In late January, we mapped the meal replacement category and arrived at a slightly uncomfortable conclusion. Strip away branding, and most products were beginning to look the same. The same 500ml bottle. The same micronutrient grid. The same protein-led approach to satiety, increasingly supplemented with fibre.
At the time, it felt like a category approaching maturity. Today, it looks more like one consolidating.
Danone has agreed to acquire Huel - the UK-founded “complete nutrition” brand known for its powders, ready-to-drink meals, and subscription-led model - in a deal reported at approximately €1bn, announced in March 2026 and currently subject to regulatory approval.
Two companies, arriving from very different starting points, now sit within the same operating logic.
One built on clinical nutrition, scaled through supermarkets and trust. The other founded in the UK in 2014, built online, and shaped by a loyal, repeat-heavy customer base around the idea of “complete nutrition.” By 2024, Huel had reached roughly £214m in revenue, expanding from powders into ready-to-drink meals, bars, and a broader ecosystem of functional products.
Placed side by side, the overlap is difficult to ignore.
Danone’s history has always been anchored in the idea of health delivered through everyday consumption. From its origins in early probiotic research to its expansion into plant-based, the company has consistently operated in categories that sit close to daily life.
But those categories have largely lived alongside existing habits. Milk next to milk. Yogurt as part of a meal or snack. They integrate, rather than reorganise.
Huel operates differently. It does not sit neatly within established patterns. It compresses them.
That is what makes this acquisition feel so aligned. Danone brings scale, infrastructure, and a deep familiarity with regulation and global distribution. Huel brings a behaviour that is already embedded: a consumer who has accepted that eating can be reduced to something repeatable, predictable, and nutritionally sufficient.
Together, they close a gap neither could fully address alone.
The idea that one product can stand in for an entire meal already feels too blunt for the conditions now shaping consumption. Appetite is shifting, in some cases pharmacologically. Grocery spend is already shifting following GLP-1 adoption.
According to recent data, around 12.4% of U.S. adults, roughly one in eight, are now using GLP-1 medications, with usage more than doubling year-on-year. Within six months of adoption, grocery spend falls by around 5.3%, with restaurant spend down a further ~8%. This is considerable reallocation.
Consumption moves away from snacks, sweets, and excess, and toward protein, functional formats, and nutritionally dense products that justify their place in a smaller, more deliberate eating pattern.
Under those conditions, the category begins to fracture and what emerges is a move toward products designed for particular moments in modern day to day life. This is already visible at the edges. A new “GLP-1 nutrition” market is forming, projected to grow from $4.1bn in 2025 to $13bn by 2035. Protein and macronutrient blends dominate, but clinical and commercial systems are beginning to overlap too. Ready-to-drink formats are now appearing in hospitals, outpatient programmes, and telehealth bundles.
The category is no longer defined by convenience alone. It is being redefined by compliance.
.png)
.png)
